Abstract
RNA interference (RNAi) is a process of double-stranded RNA-dependent post-transciptional gene silencing that occurs mainly in the mRNA processing bodies (P-bodies) of cells. It has become the most powerful and widely used gene strategy for genetic analysis and molecular therapeutics, based on the highly specific and efficient silencing of target genes. The key challenge for achieving effective RNAi in vitro and in vivo is its delivery to the desired organs and into the target cells. The RNAi delivery systems can be either non-viral or viral vectors. The main candidate for RNAi as a therapeutical tool is the viral-based vectors, including retroviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses and herpes simplex virus-1 (HSV-1). There is a high potential for clinical use of RNAi in treatment of a wide variety of human diseases, including genetic disorders, infectious diseases and cancer. This paper reviews the designs of inducible, tissue specific, hybrid, oncolytic and high-throughput RNAi vectors based on plasmids or viruses, and discusses their specificity, efficiency and safety.
Keywords: RNAi, processing body, viral vectors, therapeutical design
Current Pharmaceutical Design
Title: The Design of Vectors for RNAi Delivery System
Volume: 14 Issue: 13
Author(s): Qi Zhao Wang, Ying Hui Lv, Yong Diao and Ruian Xu
Affiliation:
Keywords: RNAi, processing body, viral vectors, therapeutical design
Abstract: RNA interference (RNAi) is a process of double-stranded RNA-dependent post-transciptional gene silencing that occurs mainly in the mRNA processing bodies (P-bodies) of cells. It has become the most powerful and widely used gene strategy for genetic analysis and molecular therapeutics, based on the highly specific and efficient silencing of target genes. The key challenge for achieving effective RNAi in vitro and in vivo is its delivery to the desired organs and into the target cells. The RNAi delivery systems can be either non-viral or viral vectors. The main candidate for RNAi as a therapeutical tool is the viral-based vectors, including retroviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses and herpes simplex virus-1 (HSV-1). There is a high potential for clinical use of RNAi in treatment of a wide variety of human diseases, including genetic disorders, infectious diseases and cancer. This paper reviews the designs of inducible, tissue specific, hybrid, oncolytic and high-throughput RNAi vectors based on plasmids or viruses, and discusses their specificity, efficiency and safety.
Export Options
About this article
Cite this article as:
Wang Zhao Qi, Lv Hui Ying, Diao Yong and Xu Ruian, The Design of Vectors for RNAi Delivery System, Current Pharmaceutical Design 2008; 14 (13) . https://dx.doi.org/10.2174/138161208799316357
DOI https://dx.doi.org/10.2174/138161208799316357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening Methods of Preparation of Multifunctional Microbubbles and their In Vitro / In Vivo Assessment of Stability, Functional and Structural Properties
Current Pharmaceutical Design Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Current Medicinal Chemistry Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Strategies for Targeting Lentiviral Vectors
Current Gene Therapy Synergistic Combination of Doxorubicin and Paclitaxel Delivered by Blood Brain Barrier and Glioma Cells Dual Targeting Liposomes for Chemotherapy of Brain Glioma
Current Pharmaceutical Biotechnology Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer
Current Gene Therapy In Vivo Application and Tracking of Baculovirus
Current Gene Therapy Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Critical Role of IL-8 Targeting in Gliomas
Current Medicinal Chemistry